Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Leukemia; solid tumors

Human leukocyte antigen (HLA); Wilms tumor 1 (WT1)

Mouse and cell culture studies suggest a human mAb targeting the WT1-HLA complex could help treat leukemia and solid tumors. In panels of cells from healthy donors and patients, the human mAb, called ESK1, bound to the majority of leukemic and solid tumor cell lines that were positive for WT1 and the WT1-HLA complex. In a mouse xenograft model for acute lymphoblastic leukemia (ALL), ESK1 decreased tumor burden and increased survival compared with a control IgG. Next steps include evaluating ESK1 in additional animal safety studies and scaling up manufacturing of the antibody.
Eureka Therapeutics Inc. has ESK1 in preclinical development to treat leukemia.
GlaxoSmithKline plc's GSK2130579, an antigen-specific cancer immunotherapeutic utilizing recombinant WT1, is in Phase II testing to treat acute myelogenous leukemia (AML) and Phase I testing to treat breast cancer.
Inovio Pharmaceuticals Inc. has a WT1 DNA vaccine in Phase II testing to treat leukemia (see mAb attack on WT1, page 5).

SciBX 6(12); doi:10.1038/scibx.2013.286
Published online March 28, 2013

Patent applications filed; available for licensing from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics
Contact: Sharon Seiler, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
e-mail:

seilers@mskcc.org
Contact: Elisa Pan, Eureka Therapeutics Inc., Emeryville, Calif.
e-mail:

elisa_pan@eurekainc.com

Dao, T. et al. Sci. Transl. Med.; published online March 13, 2013;
doi:10.1126/scitranslmed.3005661
Contact: David A. Scheinberg, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
e-mail:

d-scheinberg@ski.mskcc.org
Contact: Cheng Liu, Eureka Therapeutics Inc., Emeryville, Calif.
e-mail:

cheng_liu@eurekainc.com